Compare ASML & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | GILD |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.6B | 154.7B |
| IPO Year | 1995 | 1992 |
| Metric | ASML | GILD |
|---|---|---|
| Price | $1,342.91 | $122.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $1,369.50 | $128.62 |
| AVG Volume (30 Days) | 1.4M | ★ 6.3M |
| Earning Date | 01-28-2026 | 02-10-2026 |
| Dividend Yield | 0.50% | ★ 2.55% |
| EPS Growth | 37.86 | ★ 6514.05 |
| EPS | ★ 28.34 | 6.42 |
| Revenue | ★ $37,666,043,037.00 | $29,087,000,000.00 |
| Revenue This Year | $17.25 | $3.67 |
| Revenue Next Year | $4.75 | $3.43 |
| P/E Ratio | $44.59 | ★ $19.32 |
| Revenue Growth | ★ 22.77 | 2.79 |
| 52 Week Low | $578.51 | $89.83 |
| 52 Week High | $1,291.48 | $128.70 |
| Indicator | ASML | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 74.42 | 49.84 |
| Support Level | $1,249.62 | $119.33 |
| Resistance Level | $1,291.48 | $124.48 |
| Average True Range (ATR) | 26.32 | 2.85 |
| MACD | 16.88 | 0.04 |
| Stochastic Oscillator | 94.83 | 62.65 |
ASML is the market leader in lithography systems for manufacturing semiconductors. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's largest clients are TSMC, Samsung, and Intel.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).